--- title: "ProtoKinetix (PKTX) news: Nasdaq notice" url: "https://aibio.space/companies/protokinetix/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PKTX Nasdaq notice news: ProtoKinetix files late-filing notice for its June 30, 2026 quarterly report. ProtoKinetix, Inc. (OTC: PKTX), United States." --- PKTX ProtoKinetix, Inc. OTC · United States # ProtoKinetix (PKTX) news PKTX Nasdaq notice news Distress · 2026-08-14 ## [ProtoKinetix files late-filing notice for its June 30, 2026 quarterly report](https://aibio.space/news/protokinetix-files-late-filing-notice-june-30-2026-quarterly-report/) The notice also says its 2025 Form 10-K and its March 31, 2026 Form 10-Q have not been filed. The company cites delays in finishing its financial statements and an auditor review. ## Latest ProtoKinetix news 1. 2026-06-17 Company Updates [ProtoKinetix names Keith Brunt president and adds two directors](https://aibio.space/news/protokinetix-names-keith-brunt-president-adds-two-directors/) ProtoKinetix appointed Keith Brunt as a director and president and added Michael Jones and Jason Lamp to its board on June 17, 2026, after a March 31, 2026 resignation. ## ProtoKinetix at a glance - **Ticker**: PKTX - **Listing**: OTC - **Country**: United States - **Cash, Dec 31, 2025**: $1,118 ### Related companies - [Mirum Pharmaceuticals](https://aibio.space/companies/mirum-pharmaceuticals/) NASDAQ: MIRM - [Ligand Pharmaceuticals](https://aibio.space/companies/ligand-pharmaceuticals/) NASDAQ: LGND - [Clene](https://aibio.space/companies/clene/) NASDAQ: CLNN - [Cumberland Pharmaceuticals](https://aibio.space/companies/cumberland-pharmaceuticals/) NASDAQ: CPIX - [TherapeuticsMD](https://aibio.space/companies/therapeuticsmd/) NASDAQ: TXMD - [Ionis Pharmaceuticals](https://aibio.space/companies/ionis-pharmaceuticals/) NASDAQ: IONS - [Protagenic Therapeutics](https://aibio.space/companies/protagenic-therapeutics/) OTC: PTIX - [Gossamer Bio](https://aibio.space/companies/gossamer-bio/) NASDAQ: GOSS ### Also on OTC - [ESCALON MEDICAL CORP](https://aibio.space/companies/escalon-medical/) ESMC - [Sonendo](https://aibio.space/companies/sonendo/) SONX - [Renalytix](https://aibio.space/companies/renalytix/) RNLXY - [SQZ Biotechnologies](https://aibio.space/companies/sqz-biotechnologies/) SQZB - [Regen Biopharma](https://aibio.space/companies/regen-biopharma/) RGBP - [Vicarious Surgical](https://aibio.space/companies/vicarious-surgical/) RBOT ## What ProtoKinetix does ProtoKinetix, Incorporated is a research and development stage biotechnology company focused on scientific medical research of AFGPs (anti-freeze glycoproteins), which it trademarks as AAGPs. The company says it is directing major efforts toward the practical side of commercial validation, and that commercial applications for AAGPs in large markets such as targeted health care solutions are numerous. It is working with researchers, business leaders, advisors and commercial entities to bring AAGP to market. ProtoKinetix was incorporated in Nevada on December 23, 1999 as RJV Network, Inc., originally to develop an internet-based commercial real estate listing site. In July 2003 it took an assignment of license from BioKinetix Research, Incorporated for proprietary technologies to create and commercialize superantibodies. In June 2023 it announced the submission of a research paper on islet-like cells differentiated from patient-derived iPSCs for the treatment and eventual cure of Type-1 Diabetes. The company has no revenues and says it will need to increase its research and development funding, which is limited by its ability to raise money. | Product or program | What it is | Stage | |---|---|---| | AAGP | Anti-aging glycoprotein molecule for targeted health care applications | Research and development stage | | Islet-like cells for Type-1 Diabetes | Islet-like cells differentiated from patient-derived iPSCs, for diabetes research | Research paper submitted June 2023 | Summarised from the company's [10-K filed Sep 3, 2026](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001218/pktx_10k.htm). ## ProtoKinetix annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$106,613](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001218/) | [$99,625](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001218/) | | Net income (loss) | [-$393,650](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001218/) | [-$364,188](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001218/) | | Cash from operations | [-$135,377](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001218/) | [-$223,050](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001218/) | | Cash and equivalents | [$1,118](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001218/) | [$4,697](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001218/) | Latest balance sheet, Dec 31, 2025 (10-K): cash and equivalents $1,118. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ProtoKinetix Has ProtoKinetix received a Nasdaq deficiency notice? Our latest story on this, dated Aug 14, 2026: "ProtoKinetix files late-filing notice for its June 30, 2026 quarterly report". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/protokinetix-files-late-filing-notice-june-30-2026-quarterly-report/). What is the ticker symbol of ProtoKinetix? ProtoKinetix, Inc. trades under the ticker PKTX on OTC. Where is ProtoKinetix listed? ProtoKinetix, Inc. is listed on OTC. What is the SEC CIK of ProtoKinetix? The SEC Central Index Key (CIK) for ProtoKinetix, Inc. is 1128189. Its filings are on SEC EDGAR. How many shares does ProtoKinetix have outstanding? 411,630,152 shares as of 2026-09-02, per the cover page of its 10-K filed 2026-09-03. Which country or territory is ProtoKinetix listed under? Our directory records ProtoKinetix, Inc. under United States. What does ProtoKinetix do? Our directory classifies ProtoKinetix, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of ProtoKinetix? The ISIN recorded for ProtoKinetix, Inc. is US7437221002. Does aibio.space cover ProtoKinetix? aibio.space lists ProtoKinetix, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is ProtoKinetix incorporated? SEC records list its state or country of incorporation as NV. What does ProtoKinetix develop? ProtoKinetix, Incorporated is a research and development stage biotechnology company focused on scientific medical research of AFGPs (anti-freeze glycoproteins), which it trademarks as AAGPs. The company says it is directing major efforts toward the practical side of commercial validation, and that commercial applications for AAGPs in large markets such as targeted health care solutions are numerous. What is AAGP from ProtoKinetix? AAGP: Anti-aging glycoprotein molecule for targeted health care applications Stage: Research and development stage. What is Islet-like cells for Type-1 Diabetes from ProtoKinetix? Islet-like cells for Type-1 Diabetes: Islet-like cells differentiated from patient-derived iPSCs, for diabetes research Stage: Research paper submitted June 2023. Is ProtoKinetix profitable? ProtoKinetix, Inc. reported a net loss of $393,650 for the fiscal year ended Dec 31, 2025, and used $135,377 of cash in operations, per its annual report to the SEC. How much does ProtoKinetix spend on research and development? $106,613 in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: ProtoKinetix Members talk about ProtoKinetix (PKTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ProtoKinetix, newest first. Each line links the filing it comes from. 1. 2026-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001119/pktx_12b25.htm) 2. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1128189/000107997326000677/pktx_12b25.htm) 3. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1128189/000107997326000402/pktx_12b25.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:PKTX on TradingView](https://www.tradingview.com/symbols/OTC-PKTX/). ## SEC filings and registration - **SEC name**: ProtoKinetix, Inc. - **CIK**: 1128189 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PKTX (None) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 109 W. MAIN ST., DALTON, OH, 44618 - **Phone**: 330-445-4971 - **Shares outstanding**: 411,630,152 as of 2026-09-02 (10-K filed 2026-09-03) - **Former names**: RJV NETWORK INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-K](https://www.sec.gov/Archives/edgar/data/1128189/000107997326001218/pktx_10k.htm) filed 2026-09-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/pktx_8k.htm) filed 2026-06-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1128189/000155335025000111/pktx_8k.htm) filed 2025-11-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1128189/000107997325001778/pktx_8k.htm) filed 2025-11-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1128189/000107997325001708/pktx_10q-093025.htm) filed 2025-11-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1128189/000107997325001594/pktx_8k.htm) filed 2025-10-10 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1128189/000107997325001456/pktx_def14a.htm) filed 2025-09-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1128189/000107997325001254/pktx_10q-063025.htm) filed 2025-08-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001128189), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ProtoKinetix, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker PKTX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ProtoKinetix, Inc. - **Ticker**: PKTX - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US7437221002 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-PKTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/protokinetix/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ProtoKinetix (PKTX) news: Nasdaq notice", 2026-10-31, https://aibio.space/companies/protokinetix/